The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.
A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.
The firm plans to launch 10 new products next year, but analysts were cautious about Quidel's prospects moving forward.
Isothermal molecular assays to diagnose a parasitic infection that afflicts approximately 300 million people are moving closer to commercialization.
After years of frustration, researchers can now more definitively link a polio-like syndrome to prior infection with two common respiratory viruses.
The director of the Biomedical Advanced Research and Development Authority has launched two new funding programs in the past three years.
New outcomes data shows that the firm's test can help clinicians optimize antibiotic prescribing, but investment analysts have had mixed reactions.
Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.
While the news of the BARDA contract drove a surge in T2's stock price, it was last month's NTAP decision that has company officials and analysts encouraged.
New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
In Nature this week: epigenetic factors that prevent healthy aging and more.
A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.
NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.